Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer

Your text is mostly clear and well-structured. Here's a slightly polished version for improved clarity and flow: This is a randomized, non-inferiority study comparing radiochemotherapy to radical cystectomy in patients with muscle-invasive bladder cancer. The primary outcome is the evaluation of the non-inferiority of metastasis-free survival between the two treatments. The study population includes individuals of both sexes, aged 18 years and older, diagnosed with pure or predominant urothelial carcinoma. Participants will be randomized in a 1:1 ratio, with Arm 1 receiving maximal TURBT followed by neoadjuvant chemotherapy and radiotherapy, and Arm 2 receiving TURBT followed by neoadjuvant chemotherapy with cisplatin, followed by radical cystectomy and bilateral pelvic lymphadenectomy.

NCT Number	NCT07008833
Lead Sponsor	Brazilian Clinical Research Institute Collaborators: Ministry of Science and Technology, Brazil
Conditions	Muscle Invasive Bladder Cancer
Enrollment	336 participants
Start Date	2026-06
Primary Completion	2031-12 (estimated)
Study Completion	2032-02 (estimated)
Updated on ClinicalTrials.gov	2026-02-12